Supplementary Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Clara Albanese(University of L'Aquila), Marina Ciomei(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Francesco Colotta(Humanitas University), Ciro Mercurio(Mylan (Switzerland)), Nilla Avanzi(Nerviano Medical Sciences), Maria Gabriella Brasca(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Rachele Alzani(Nerviano Medical Sciences), Veronica Patton(University of L'Aquila), Jurgen Moll, Fulvia Roletto(Nerviano Medical Sciences), Enrico Pesenti, Francesco Fiorentini(Nerviano Medical Sciences), Giuseppe Locatelli(University of L'Aquila), Claudio Festuccia(University of L'Aquila), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
CD46 Is a Cellular Receptor for Human Herpesvirus 6
|Cell|1999|525
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury
|Proceedings of the National Academy of Sciences|2004|339
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205